Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals UTB by Year
UTB — Accrued interest and penalties at period-end ($M) ($M)
Vertex Pharmaceuticals UTB: $95.7M in FY2025, up 15.9% from a year earlier.
Latest, FY2025
95.7
Period ended Dec 31, 2025
Change on a year earlier
+15.9%
82.6 in FY2024
History
10 years
Since FY2015
Sources
9
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Income Taxes).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | UTB — Accrued interest and penalties at period-end ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 95.7 | +15.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 82.6 | -33.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 124 | +216.6% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 39.2 | – | Form 10-K (filed 2024-02-15) ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2023-02-10) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2020-02-13) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2018-02-15) ↗ |
| FY2016 | Dec 31, 2016 | 0 | – | Form 10-K (filed 2017-02-23) ↗ |
| FY2015 | Dec 31, 2015 | 0 | – | Form 10-K (filed 2016-02-16) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals UTB ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/utb-int-accrued
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.